ClinicalTrials.gg
CompletedNCT05104125Updated May 16, 2025

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

A Phase 2 interventional study of ASC40 25mg and ASC40 50mg in Acne Vulgaris, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Enrollment
13th of 33
180 · median 100
Started
2022
with 3 others
Phase 2
3 of 35
2 open now
Registered
16th of 35
by date
Lead sponsor
3 of 35
Ascletis Pharmaceuticals Co., Ltd.

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 2, and was the 16th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne vulgaris
  • ASC40
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18-40 years old (including 18 and 40 years old);
  • Investigator's Global Assessment of subject at baseline period was at 3-4.
  • Facial skin lesions of subject need counting as follows: 30 \~ 75 inflammatory lesions (the total number of papules, pustules and nodules is 30 \~ 75, including no more than 2 nodules), 30 \~ 100 non-inflammatory lesions (the total number of open and closed comedones is 30 \~ 100);

Key Exclusion Criteria:

  • Known to be allergic or hypersensitive to ASC40 tablets;
  • Facial nodules of subject is more than 2 facial nodules
  • The subject with cystic acne
  • Subject with secondary acne such as occupational acne (e.g., chloroacne) and acne caused by (e.g., chloroacne or acne caused by drugs);
  • Serum , ALT≥3ULN and Cr exceeded the
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Experimental group 1

    ASC40 25mg for 12 weeks

    Drug: ASC40 25mg

  • Experimental
    Experimental group 2

    ASC40 50mg for 12 weeks

    Drug: ASC40 50mg

  • Experimental
    Experimental group 3

    ASC40 75mg for 12 weeks

    Drug: ASC40 75mg

  • Placebo comparator
    Placebo group

    Placebo for 12 weeks

    Drug: Placebo

Interventions

  • 25mg of ASC40 orally once daily for 12 weeks.

  • 50mg of ASC40 orally once daily for 12 weeks.

  • 75mg of ASC40 orally once daily for 12 weeks.

  • DrugPlacebo

    Placebo orally once daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage change of total lesion count compared with baseline and week 12.

    Time frame: Baseline to week 12

  2. Ratio of subjects, whose IGA grades was decreased by ≥2 grades compared with baseline at week 12.

    Time frame: Baseline to week 12

Secondary outcomes

  1. The changes status and changes of average percentage of inflammatory skin lesions count, non-inflammatory skin lesions count and total skin lesions count compared with baseline.

    Time frame: Baseline to week 2, 4, 8 and 12

  2. Ratio of subjects, whose GA grades was 1 or 0, or GA grades was decreased y ≥2 grades compared with baseline and Improvements in classification

    Time frame: Baseline to week 2, 4, 8 and 12

07

Study locations

1 site
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 200000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Apr 2023, 14 months.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 14 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 2, 2021
StartActual
Jan 12, 2022
Primary completionActual
Apr 10, 2023
CompletionActual
Apr 10, 2023
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05104125
Responsible party
Sponsor
First posted
Nov 2, 2021
Start date
Jan 12, 2022
Primary completion
Apr 10, 2023
Completion
Apr 10, 2023
Last update
May 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion